Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology


Crinetics VP of clinical endocrinology, Peter J. Trainer, M.D., will review preclinical and Phase 1 clinical results of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces July 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces June 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Presents Clinical and Research Results at ENDO 2022


Crinetics Pharmaceuticals to present findings from Phase 1 programs of CRN04894 and CRN04777 as well as discovery of PTHR1 antagonist at ENDO 2022.

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference


Crinetics Pharmaceuticals management to participate in a fireside chat at the 2022 JMP Securities Life Sciences Conference